Search Results

You searched for : LatestPfizerNews

	FIRST PARTICIPANT DOSED IN PFIZER’S PIVOTAL PHASE 3 TALAPRO-3 COMBINATION STUDY OF TALAZOPARIB AND ENZALUTAMIDE ... Jun 23
	DATA PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE SHOWS PFIZER’S TOFACITINIB MEETS PRIMARY ENDPOINT IN BRAZILIAN STUDY IN PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA It is important to note that tofacitinib has not been approved or authorized for use by any regulatory authority worldwide for the treatment of COVID-... Jun 17
	PFIZER AND BIONTECH TO PROVIDE 500 MILLION COVID-19 VACCINE TO U.S. GOVERNMENT FOR DONATION TO POOREST NATIONS These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and ... Jun 10
	Pfizer and Biontech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize Pseudovirus bearing the SARS-COV-2 U.K While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-... Jan 21
	Pfizer invests $120 million in biotechnology innovation through the Pfizer breakthrough growth initiative Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the ... Jan 13
	Pfizer doses first participants in phase 3 study for Duchenne Muscular Dystrophy investigational Gene Therapy CIFFREO is a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study.... Jan 07
	US FDA accepts regulatory submission from PFIZER and OPKO for review of somatrogon Pfizer inc. and OPKO Health Inc. announced today that the USFDA has accepted for filing the initial Biologics License Application for somatrogon, a long-acting ... Jan 05
	PFIZER AND BIONTECH TO SUPPLY THE U.S. WITH 100 MILLION ADDITIONAL DOSES OF COVID-19 VACCINE ... Dec 24
	U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE BIOLOGICS LICENSE APPLICATION FOR PFIZER’S INVESTIGATIONAL 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE The FDA’s acceptance of our application for 20vPnC is yet another significant milestone in Pfizer’s continuing efforts to help protect adults against pneumococcal ... Dec 09
	PFIZER REPORTS POSITIVE CLINICAL DATA FOR BCMA-CD3 BISPECIFIC ANTIBODY IN MULTIPLE MYELOMA ... Dec 08
	PFIZER AND SANGAMO ANNOUNCE UPDATED PHASE 1/2 RESULTS FOR HEMOPHILIA A GENE THERAPY We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of ... Dec 07
	PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19 ... Dec 02
	PFIZER DOSES FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING ANTI-TFPI INVESTIGATIONAL THERAPY An anti-tissue factor pathway inhibitor being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.... Nov 23
	RESULTS FROM PHASE 3 CROWN TRIAL OF PFIZER’S LORBRENA IN PREVIOUSLY UNTREATED ALK-POSITIVE LUNG CANCER PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE ... Nov 19
	PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY ... Nov 09
	FDA GRANTS PRIORITY REVIEW AND EMA ACCEPTS REGULATORY SUBMISSION FOR PFIZER’S ABROCITINIB FOR PATIENTS WITH ATOPIC DERMATITIS ... Oct 27
	PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT We are proud of the transformative impact IBRANCE has had on the treatment of HR+, HER2- metastatic breast cancer... Oct 09
	Pfizer reports weekly Somatrogon is more effective in human growth deficiency Clinical Study proves weekly administration of Somatrogon more effective in treating human growth deficiency disease... Oct 09
	PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT We are proud of the transformative impact IBRANCE has had on the treatment of HR+, HER2- metastatic breast cancer... Oct 09
	PFIZER AND SANGAMO DOSE FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING HEMOPHILIA The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to ... Oct 07
	BIONTECH AND PFIZER INITIATE ROLLING SUBMISSION TO EUROPEAN MEDICINES AGENCY FOR SARS-COV-2 VACCINE Pfizer Inc. today announced the initiation of a rolling submission to the EMA for SARS-Cov-2 vaccine... Oct 06
	PFIZER RECEIVES FDA FAST TRACK DESIGNATION FOR DUCHENNE MUSCULAR DYSTROPHY Pfizer Inc. today announced that its investigational gene therapy candidate being developed to treat Duchenne muscular dystrophy ... Oct 01
	U.S. FDA APPROVES PFIZER’S XELJANZ FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS Pfizer Inc. announced XELJANZ (tofacitinib) for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis... Sep 28
	FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR PFIZER’S XALKORI Pfizer Inc. today announced that the U.S. FDA has accepted and granted priority review to the Company’s supplemental New Drug Application for XALKORI ... Sep 23
	Pfizer Inc & BioNTech chooses mRNA-based vaccine candidate for trial Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and Pivotal Phase Global Study ... Aug 01
25 Matching result(s) found!

-Advertisements-

Trending Now
	Dark Web Health Data: Why Medical Records MatterOctober 27, 2026
	Can Conversational AI Improve Patient Follow-Up After Discharge?October 27, 2026
	UAE fast-tracking advanced diagnostics as global market heads for US$152 billionOctober 26, 2026
	How Digital Check-In Can Support More Accessible Patient JourneysOctober 26, 2026
	The Role of Consent Communication in Digital Healthcare ServicesOctober 26, 2026
	How Data Analytics Is Transforming Hospital Decision-MakingOctober 26, 2026
	Hospital Intelligence: The Next Big Leadership Shift in India October 26, 2026
	What Patients Should Expect From a Well-Designed Health Checkup ProgrammeOctober 23, 2026
	Building Stronger Community-Based Screening ProgrammesOctober 23, 2026
	Gulf Medical University Ranks 1st for International Student Ratio in QS Arab Region Rankings 2027October 22, 2026
	Arthritis Is Not Just an Elderly Person's Disease: Why Younger Adults Are Also Developing Joint ProblemsOctober 22, 2026
	Krishna Automotive strengthens its operations in Hyderabad. Enhances customer offering with BMW Service Workshop and BMW Premium Selection.October 22, 2026
	CTR-JK Tyre FMSCI Indian National Car Racing Championship 2026 set for season opener in CoimbatoreOctober 22, 2026
	The Anonymous Indian Charitable Trust (TAICT) Wins Sustainable Organization Award 2026October 22, 2026
	Vinod Intelligent Cookware Targets Delhi’s Premium Cookware Market with Freya Brand ActivationOctober 22, 2026
	Apollo Hospitals and Avadi Police Commissionerate Organise Health Camp for Police Personnel and Their Families Under ‘Kaval Kudumbam’ SchemeOctober 22, 2026
	TAMPOS Midterm Conference 2026 Brings Together 150 Oncologists to Advance Cancer Care Across Tamil NaduOctober 22, 2026
	Shades of Pink: Apollo Athenaa Women's Cancer Centres puts the spotlight on breast health awarenessOctober 22, 2026
	How Health Systems Can Reduce Missed Follow-UpsOctober 21, 2026
	What Good Care Coordination Looks Like Across Multiple ProvidersOctober 21, 2026

Search Results

FIRST PARTICIPANT DOSED IN PFIZER’S PIVOTAL PHASE 3 TALAPRO-3 COMBINATION STUDY OF TALAZOPARIB AND ENZALUTAMIDE

DATA PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE SHOWS PFIZER’S TOFACITINIB MEETS PRIMARY ENDPOINT IN BRAZILIAN STUDY IN PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA

PFIZER AND BIONTECH TO PROVIDE 500 MILLION COVID-19 VACCINE TO U.S. GOVERNMENT FOR DONATION TO POOREST NATIONS

Pfizer and Biontech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize Pseudovirus bearing the SARS-COV-2 U.K

Pfizer invests $120 million in biotechnology innovation through the Pfizer breakthrough growth initiative

Pfizer doses first participants in phase 3 study for Duchenne Muscular Dystrophy investigational Gene Therapy

US FDA accepts regulatory submission from PFIZER and OPKO for review of somatrogon

PFIZER AND BIONTECH TO SUPPLY THE U.S. WITH 100 MILLION ADDITIONAL DOSES OF COVID-19 VACCINE

U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE BIOLOGICS LICENSE APPLICATION FOR PFIZER’S INVESTIGATIONAL 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

PFIZER REPORTS POSITIVE CLINICAL DATA FOR BCMA-CD3 BISPECIFIC ANTIBODY IN MULTIPLE MYELOMA

PFIZER AND SANGAMO ANNOUNCE UPDATED PHASE 1/2 RESULTS FOR HEMOPHILIA A GENE THERAPY

PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19

PFIZER DOSES FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING ANTI-TFPI INVESTIGATIONAL THERAPY

RESULTS FROM PHASE 3 CROWN TRIAL OF PFIZER’S LORBRENA IN PREVIOUSLY UNTREATED ALK-POSITIVE LUNG CANCER PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

FDA GRANTS PRIORITY REVIEW AND EMA ACCEPTS REGULATORY SUBMISSION FOR PFIZER’S ABROCITINIB FOR PATIENTS WITH ATOPIC DERMATITIS

PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT

Pfizer reports weekly Somatrogon is more effective in human growth deficiency

PENELOPE-B TRIAL OF IBRANCE (PALBOCICLIB) IN EARLY BREAST CANCER DID NOT MEET PRIMARY ENDPOINT

PFIZER AND SANGAMO DOSE FIRST PARTICIPANT IN PHASE 3 STUDY EVALUATING HEMOPHILIA

BIONTECH AND PFIZER INITIATE ROLLING SUBMISSION TO EUROPEAN MEDICINES AGENCY FOR SARS-COV-2 VACCINE

PFIZER RECEIVES FDA FAST TRACK DESIGNATION FOR DUCHENNE MUSCULAR DYSTROPHY

U.S. FDA APPROVES PFIZER’S XELJANZ FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR PFIZER’S XALKORI

Pfizer Inc & BioNTech chooses mRNA-based vaccine candidate for trial

Trending Now